Project Grant F32CA301815
Award Date 12/17/25
Completion Date 12/31/26
Dollars Obligated $150K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
- This Project Grant award, funded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), provides $1,295,508 to The Washington University to conduct research on drugging the NRF2 transcription factor to improve radiation therapy for head and neck squamous cell carcinoma. The project aims to evaluate two distinct NRF2 inhibitors - VVD065, a potent small molecule that induces NRF2 degradation, and pyrimethamine, an FDA-approved drug found to inhibit NRF2 signaling. Under a...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to define key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identify pathways that can restore viability in MTAP-deleted cancer cells. The $442,089 award to Yale University will leverage a genome-scale CRISPR activation platform to identify genes that modulate sensitivity to PRMT5 pathway inhibition. The research aims to...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...
- The National Cancer Institute (NCI) awarded a $105,189 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Minnesota to support research aimed at "Deciphering APOBEC Inhibition: Unraveling Structural Dynamics via Viral Protein and Nanobody Interactions." The project seeks to advance the structural understanding of the APOBEC3A and APOBEC3B enzymes, which play critical roles in both host defense and cancer mutagenesis....
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted AURKA (Aurora-A Kinase) inhibitor called NN-01-195. The goal is to investigate the feasibility and potential of this novel chimeric compound, which fuses an HSP90 inhibitor with an AURKA inhibitor, as a cancer treatment approach. The proposed research aims to evaluate the...
- This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,916.00 to the University of Massachusetts Medical School to investigate factors contributing to chemoresistance in BRCA mutant hereditary breast and ovarian cancers. The overall goal is to gain a new understanding of the mechanisms behind chemoresistance in these cancers, which frequently develop resistance to existing chemotherapies and PARP inhibitors. The research aims to...
- This Project Grant award of $524,815 was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Saint Louis University (SLU) on August 28, 2025. The grant supports research aimed at understanding the mechanisms of homologous recombination (HR), a DNA repair pathway critical for maintaining genomic stability. The key focus is on elucidating how mediator proteins and RAD51 paralogs facilitate the formation and stabilization of the RAD51 nucleoprotein...